Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.20)
# 2,833
Out of 5,135 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $23.19 | -13.76% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $27.48 | -45.41% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.10 | -43.26% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $26.65 | +87.62% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $128.38 | +5.94% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $8.45 | +89.35% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.09 | +582.07% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.99 | +504.53% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $18.38 | +493.04% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.61 | +206.51% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.95 | +153.16% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.06 | +1,003.75% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $24.58 | -75.59% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.32 | +186.89% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $151.11 | -84.78% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $54.85 | -34.37% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $23.19
Upside: -13.76%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $27.48
Upside: -45.41%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.10
Upside: -43.26%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $26.65
Upside: +87.62%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $128.38
Upside: +5.94%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $8.45
Upside: +89.35%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.09
Upside: +582.07%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.99
Upside: +504.53%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $18.38
Upside: +493.04%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.61
Upside: +206.51%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.95
Upside: +153.16%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $9.06
Upside: +1,003.75%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $24.58
Upside: -75.59%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.32
Upside: +186.89%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $151.11
Upside: -84.78%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $54.85
Upside: -34.37%